13F filerCIK 1061768 ↗
Baupost Group
You are looking at Q2 2017. See the latest, Q3 2026 →
Reported value
$8.75B
+3.1% on the quarter before
Positions
41
4 new, 6 sold out
Top 10
72.1%
of the value
Est. gain
−$130.2M
on stocks held all quarter
Est. return
−1.7%
on those stocks since Q1 2017
Positions as of Jun 30, 2017, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2017. Striped tiles are options.
Largest buys
Since Q1 2017, sized at quarter-end prices.
- Synchrony Finl~$346.8MAdded, 7.1% → 10.0% of the portfolio+11,630,030 shares
- Antero Res Corp~$144.0MAdded, 3.9% → 5.2% of the portfolio+6,665,115 shares
- Qorvo~$114.9MAdded, 5.8% → 6.5% of the portfolio+1,814,486 shares
- Avis Budget Group~$109.1MNew, 0.0% → 1.2% of the portfolio+4,000,000 shares
- Express Scripts Hldg Co~$84.8MAdded, 1.0% → 1.9% of the portfolio+1,328,272 shares
- Cardinal Health Inc~$77.9MAdded, 1.0% → 1.8% of the portfolio+1,000,000 shares
- Silver Run Acquisition~$67.0MNew, 0.0% → 0.8% of the portfolio+6,615,552 shares
- Spirit Rlty Cap Inc New~$66.7MNew, 0.0% → 0.8% of the portfolio+9,000,000 shares
- Forward Pharma A/S~$16.0MAdded, 1.4% → 1.5% of the portfolio+788,652 shares
- Paratek Pharmaceuticals Inc~$8.4MAdded, 0.5% → 0.7% of the portfolio+350,000 shares
Largest sells
Since Q1 2017, sized at quarter-end prices.
- Innoviva Inc~$160.1MSold out, 1.9% → 0.0% of the portfolio−11,573,663 shares
- Mckesson Corp~$148.3MSold out, 1.7% → 0.0% of the portfolio−1,000,000 shares
- Silver Run Acquisition~$69.0MSold out, 0.8% → 0.0% of the portfolio−6,615,554 shares
- Liberty Interactive Corp~$65.9MSold out, 0.8% → 0.0% of the portfolio−1,481,719 shares
- Cheniere Energy Inc~$48.7MCut, 12.1% → 11.5% of the portfolio−1,000,000 shares
- Syngenta Ag~$46.7MSold out, 0.6% → 0.0% of the portfolio−527,968 shares
- Amerisourcebergen Corp~$44.5MSold out, 0.5% → 0.0% of the portfolio−502,474 shares
- Credit Accep Corp Mich~$37.5MCut, 0.6% → 0.3% of the portfolio−145,700 shares
- American Intl Group Inc~$19.1MCut, 0.3% → 0.1% of the portfolio−904,200 shares
- Liberty Media Corp Delaware~$16.6MCut, 0.6% → 0.4% of the portfolio−690,528 shares
Holdings
As of Jun 30, 2017; changes in shares since Mar 31, 2017.
| Holding | Value | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cheniere Energy IncCOM NEW · shares −4.6% · price +3.0% | 11.5% | $1.01B | +$29.8M | ||||||
| Synchrony FinlCOM · shares +66% · price −13.1% | 10.0% | $873.6M | −$79.1M | ||||||
| Viasat IncCOM · shares 0% · price +3.7% | 10.0% | $871.1M | +$31.3M | ||||||
| Colony Northstar IncCL A COM · shares 0% · price +9.1% | 7.7% | $675.0M | +$56.5M | ||||||
| Allergan PlcSHS · shares 0% · price +1.7% | 6.8% | $591.3M | +$10.1M | ||||||
| QorvoCOM · shares +25% · price −7.6% | 6.5% | $569.9M | −$37.7M | ||||||
| Twenty First Centy Fox IncCL A · shares 0% · price −12.5% | 6.2% | $542.4M | −$77.5M | ||||||
| Antero Res CorpCOM · shares +46% · price −5.3% | 5.2% | $457.5M | −$17.4M | ||||||
| Theravance Biopharma IncCOM · shares 0% · price +8.2% | 4.2% | $369.5M | +$28.0M | ||||||
| Pbf Energy IncCL A · shares 0% · price +0.4% | 4.0% | $350.0M | +$1.4M | ||||||
| Dell Technologies IncCOM CL V · shares 0% · price −4.6% | 3.9% | $345.4M | −$16.8M | ||||||
| QualcommCOM · shares 0% · price −3.7% | 3.3% | $288.0M | −$11.1M | ||||||
| Twenty First Centy Fox IncCL B · shares 0% · price −12.3% | 2.3% | $202.8M | −$28.5M | ||||||
| Keryx Biopharmaceuticals IncCOM · shares 0% · price +17.4% | 2.1% | $186.5M | +$27.6M | ||||||
| Express Scripts Hldg CoCOM · shares +108% · price −3.1% | 1.9% | $163.2M | −$2.5M | ||||||
| Cardinal Health IncCOM · shares +97% · price −4.5% | 1.8% | $158.2M | −$3.7M | ||||||
| Veritiv CorpCOM · shares 0% · price −13.1% | 1.6% | $137.0M | −$20.7M | ||||||
| Forward Pharma A/SSPONSORED ADR · shares +14% · price −5.5% | 1.5% | $129.4M | −$6.6M | ||||||
| Avis Budget GroupCOM · shares New | 1.2% | $109.1M | — | ||||||
| Atara Biotherapeutics IncCOM · shares 0% · price −31.9% | 0.86% | $75.0M | −$35.1M | ||||||
| ChipMOS TechnologiesSPONSORED ADR · shares 0% · price +11.4% | 0.79% | $69.4M | +$7.1M | ||||||
| Silver Run AcquisitionCOM CL A · shares New | 0.77% | $67.0M | — | ||||||
| Spirit Rlty Cap Inc NewCOM · shares New | 0.76% | $66.7M | — | ||||||
| Paratek Pharmaceuticals IncCOM · shares +17% · price +25.2% | 0.66% | $57.7M | +$9.9M | ||||||
| Gty Technology Holdings IncUNIT 99/99/9999 · shares 0% · price +1.4% | 0.53% | $46.0M | +$616,000 | ||||||
| Total 41 positions | 100% | $8.75B | −$130.2M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2017 to Q2 2017: 35 stocks held throughout, down $130.2M (−1.7%).
- Colony Northstar Inc+$56.5M+9%
- Viasat Inc+$31.3M+4%
- Cheniere Energy Inc+$29.8M+3%
- Theravance Biopharma Inc+$28.0M+8%
- Keryx Biopharmaceuticals Inc+$27.6M+17%
- Twenty First Centy Fox Inc−$28.5M−12%
- Atara Biotherapeutics Inc−$35.1M−32%
- Qorvo−$37.7M−8%
- Twenty First Centy Fox Inc−$77.5M−13%
- Synchrony Finl−$79.1M−13%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | $5.05B−7% | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | $5.42B+6% | SEC ↗ |
| Q1 2026 | May 14, 2026 | $5.12B−3% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $5.28B+10% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $4.79B+16% | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | $4.13B+18% | SEC ↗ |
| Q1 2025 | May 14, 2025 | $3.50B+2% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $3.43B−2% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $3.52B−3% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $3.63B−0% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $3.65B−20% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $4.59B−12% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $5.21B−7% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $5.61B−4% | SEC ↗ |
| Q1 2023 | May 12, 2023 | $5.85B−5% | SEC ↗ |
| Q4 2022 | Feb 13, 2023 | $6.13B+6% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $5.79B−14% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $6.77B−27% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $9.30B−8% | SEC ↗ |
| Q4 2021 | Feb 11, 2022 | $10.13B−7% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $10.88B−12% | SEC ↗ |
| Q2 2021 | Aug 13, 2021 | $12.33B−2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $12.56B+16% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $10.84B+17% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $9.25B+15% | SEC ↗ |
| Q2 2020 | Aug 13, 2020 | $8.01B+18% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $6.77B−25% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $9.06B+3% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $8.83B−20% | SEC ↗ |
| Q2 2019 | Aug 13, 2019 | $11.05B−7% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $11.90B+3% | SEC ↗ |
| Q4 2018 | Feb 13, 2019 | $11.52B−12% | SEC ↗ |
| Q3 2018 | Nov 15, 2018 (amended) | $13.06B+14% | SEC ↗ |
| Q2 2018 | Aug 13, 2018 | $11.44B+10% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $10.37B+3% | SEC ↗ |
| Q4 2017 | Feb 13, 2018 | $10.11B+26% | SEC ↗ |
| Q3 2017 | Nov 13, 2017 | $8.02B−8% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $8.75B+3% | SEC ↗ |
| Q1 2017 | May 25, 2017 (amended) | $8.49B+11% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $7.67B+9% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $7.04B−4% | SEC ↗ |
| Q2 2016 | Aug 12, 2016 | $7.37B+6% | SEC ↗ |
| Q1 2016 | May 13, 2016 | $6.92B | SEC ↗ |